Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Middle East and Turkey Hemophilia Treatment Market Insights

Hemophilia is treated with recombinant coagulation factor, plasma derived coagulation factor, antifibrinolytic agents, and desmopressin. Most of the patients with hemophilia prefer factor replacement therapy as primary treatment, owing to its positive outcomes. Increasing approval and launches of recombinant coagulation factor in the Middle East region are expected to drive growth of the recombinant coagulation factor segment in Middle East and Turkey hemophilia treatment market. For instance, in October 2017, Swedish Orphan Biovitrum AB (publ) received approval for its Alprolix (eftrenonacog alfa, Coagulation Factor IX (Recombinant), for the treatment of hemophilia B, from Saudi Food & Drug Authority (SFDA) in the Kingdom of Saudi Arabia.

The Middle East and Turkey hemophilia treatment market is estimated to be valued at US$ 645.1 million in 2019, and is expected to exhibit a CAGR of 4.2% during the forecast period (2019-2027).

Figure 1. Middle East and Turkey Hemophilia Treatment Market Share (%), By Product Type, (2019 & 2027)

Middle East and Turkey Hemophilia Treatment  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Approval and launches of such novel products in the market are expected to boost the growth of Middle East and Turkey hemophilia treatment market over the forecast period

Increasing product approvals by the key players is expected to drive the market growth over the forecast period. For instance, in August 2018, Bayer AG, received the U.S. Food and Drug Administration approval for its new hemophilia A treatment product, Jivi with flexible dosing regimen. It is used for the treatment of bleeding in adults and adolescents (12 years of age and above), who were previously treated for hemophilia A. Moreover, in February 2018, Shire Plc , the local branch of the global biotech pharmaceutical Shire, received approval from the Ministry of Food and Drug Safety for Adynovate, a long-lasting factor VIII gene recombinant for hemophilia A treatment.

Furthermore, key players are focused on adopting growth strategies such as acquisitions that is expected to drive the Middle East and Turkey hemophilia treatment market growth over the forecast period. For instance, in April 2014, Baxter International Inc. acquired Chatham Therapeutics, LLC, a privately held clinical development-stage biotechnology company engaged in development of novel, gene therapy-mediated treatments for hemophilia. Baxter acquired Chatham's developmental gene therapy platform to facilitate development and commercialization of hemophilia treatment.

Middle East and Turkey Hemophilia Treatment Market- Restraints

High cost of treatment for hemophilia is a major factor, which is expected to hinder the market growth over the forecast period. Hemophilia is associated with high aggregate costs and imposes a high financial burden on individuals, and healthcare systems in emerging economies. Hemophilia is a chronic condition that requires lifelong treatment, with individual costs varying based on disease severity, complications, and treatment regimen. For instance, according to a cohort study conducted by National Center for Biotechnology Information (NCBI) in 2015, hemophilia treatment is expensive, particularly for patients with severe hemophilia. According to the study, severe hemophilia is associated with greater annual costs in both types of hemophilia. For instance, according to the study NCBI in 2015, the annual cost required for the treatment of hemophilia A is around US$ 84,766.9 and hemophilia B is around US$ 122,877. Patients with factor VIII inhibitors have costs 3.3 times higher than patients without factor VIII inhibitors. Thus, high cost of therapy is expected to hinder the market growth over the forecast period.

Middle East and Turkey Hemophilia Treatment Market- Regional Analysis

Country wise segmentation of the Middle East and Turkey Hemophilia Treatment Market include Turkey, Egypt, Israel, Saudi Arabia, UAE, and Rest of Middle East.

Among countries, Turkey is expected to witness a significant growth in the Middle East and Turkey hemophilia treatment market over the forecast period, owing to availability of the hemophilia drugs and increasing patient population are expected to propel the market growth in Turkey over the forecast period. For instance, Baxalta Incorporated produced ADYNOVATE, an antihemophilic recombinant factor indicated for the patients above 12 years suffering from Hemophilia A. It is available in Turkey and other 66 countries, globally.

Furthermore, rising support of market players and government organizations in providing access to hemophilia drugs for people is expected to fuel the market growth in Egypt over the forecast period. For instance, In November 2017, Octapharma AG, in collaboration with Project SHARE, donated 30.5 million units of human cell-line derived recombinant factor VIII product, Nuwiq, for the treatment of patients with hemophilia A in emerging economies such as Bangladesh, Cambodia, Egypt, Ethiopia, Fiji, Kenya, Myanmar, Nepal, and others.

Figure 2: Middle East and Turkey Hemophilia Treatment Market Share (%), By Country, (2019 & 2027)

Middle East and Turkey Hemophilia Treatment  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Middle East and Turkey Hemophilia Treatment Market- Competitive Landscape

Key players operating in the Middle East and Turkey hemophilia treatment market include Takeda Pharmaceutical Company Limited., Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, Grifols S.A., Sangamo Therapeutics, Inc., and  Spark Therapeutics, Inc.

Hemophilia is rare disorder, in which in which the blood does not clot properly. In this case, bleeding after an injury takes longer duration to clot. This condition is well treated with medications such as recombinant coagulation factor, plasma derived coagulation factor, antifibrinolytic agents, and desmopressin. Generally hemophilia occurs in middle age and geriatric population, and in women after child birth. Hemophilia is characterized by the lower levels of factors in the blood, which results in constant bleeding for longer duration after an injury.  

Market Dynamics

Increasing incidences of hemophilia cases is expected to drive the Middle East and Turkey hemophilia treatment market growth. For instance, according to the Annual Global Survey’s 2016 data published by World Federation of Hemophilia, around 184,723 number of people globally suffered from hemophilia in 2016. Among this, 149,764 and 29,712 patients accounted for Hemophilia A and Hemophilia B, respectively.

Rising collaboration activities among the key players in pharmaceutical industry to develop novel hemophilia treatment options is expected to drive growth of the market. For instance, in May 2017, Sangamo Therapeutics, Inc. and Pfizer Inc. entered into a collaboration for the development and commercialization of Hemophilia A gene therapy programs, which include Sangamo’s SB-525 candidate, which may benefit patients suffering from Hemophilia A.

Key features of the study:

  • This report provides in-depth analysis of the Middle East and Turkey hemophilia treatment, market size (US$ Mn), and compound annual growth rate (CAGR %) over the forecast period (2019-2027), considering 2018 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new technology launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles leading players in the Middle East and Turkey hemophilia treatment based on the following parameters – company overview, financial performance, technology portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Takeda Pharmaceutical Company Limited., Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, Grifols S.A., Sangamo Therapeutics, Inc., and Spark Therapeutics, Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future technology launches, government initiatives, technological upgradation, market expansion, and marketing tactics
  • The Middle East and Turkey hemophilia treatment report caters to various stakeholders in this market, including investors, technology manufacturers, distributors, and suppliers for Middle East and Turkey hemophilia treatment, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Middle East and Turkey Hemophilia Treatment, By Product Type:
    • Recombinant Coagulation Factor
    • Plasma Derived Coagulation Factor
    • Antifibrinolytic Agents
    • Desmopressin
  • Middle East and Turkey Hemophilia Treatment, By Disease Indication:
    • Hemophilia A
    • Hemophilia B
    • Hemophilia C
  • Middle East and Turkey Hemophilia Treatment, By Country:
    • Turkey
      • By Product Type:
        • Recombinant Coagulation Factor
        • Plasma Derived Coagulation Factor
        • Antifibrinolytic Agents
        • Desmopressin
      • By Disease Indication:
        • Hemophilia A
        • Hemophilia B
        • Hemophilia C
    • Egypt
      • By Product Type:
        • Recombinant Coagulation Factor
        • Plasma Derived Coagulation Factor
        • Antifibrinolytic Agents
        • Desmopressin
      • By Disease Indication:
        • Hemophilia A
        • Hemophilia B
        • Hemophilia C
    • Israel
      • By Product Type:
        • Recombinant Coagulation Factor
        • Plasma Derived Coagulation Factor
        • Antifibrinolytic Agents
        • Desmopressin
      • By Disease Indication:
        • Hemophilia A
        • Hemophilia B
        • Hemophilia C
    • Saudi Arabia
      • By Product Type:
        • Recombinant Coagulation Factor
        • Plasma Derived Coagulation Factor
        • Antifibrinolytic Agents
        • Desmopressin
      • By Disease Indication:
        • Hemophilia A
        • Hemophilia B
        • Hemophilia C
        • Rest of Latin America
    • UAE
      • By Product Type:
        • Recombinant Coagulation Factor
        • Plasma Derived Coagulation Factor
        • Antifibrinolytic Agents
        • Desmopressin
      • By Disease Indication:
        • Hemophilia A
        • Hemophilia B
        • Hemophilia C
    • Rest of Middle East
      • By Product Type:
        • Recombinant Coagulation Factor
        • Plasma Derived Coagulation Factor
        • Antifibrinolytic Agents
        • Desmopressin
      • By Disease Indication:
        • Hemophilia A
        • Hemophilia B
        • Hemophilia C
  • Company Profiles
    • Takeda Pharmaceutical Company Limited*.
      • Company Overview
      • Technology Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Sanofi S.A.
    • Octapharma AG
    • Swedish Orphan Biovitrum AB
    • Baxter International Inc.
    • Biogen Inc.
    • Bayer AG
    • CSL Behring
    • Ferring B.V.
    • Pfizer, Inc.
    • Kedrion
    • Novo Nordisk A/S
    • Grifols S.A
    • Sangamo Therapeutics, Inc.
    • Spark Therapeutics, Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Disease Indication
      • Market Snippet, By Country
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Technology Advancements
    • Historical Overview
    • Merger and Acquisition
    • Regulatory Scenario
    • PORTER’S Five Forces
    • PEST Analysis
  4. Middle East and Turkey Hemophilia Treatment Market, By Product Type, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Recombinant Coagulation Factor
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Plasma Derived Coagulation Factor
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Antifibrinolytic Agents
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Desmopressin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  5. Middle East and Turkey Hemophilia Treatment Market, By Disease Indication, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hemophilia A
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Hemophilia B
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Hemophilia C
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  6. Middle East and Turkey Hemophilia Treatment Market, By Country, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, By Country, 2018 and 2027 (%)
      • Y-o-Y Growth Analysis, By Country, 2016 – 2027
      • Regional Trends
    • Turkey
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
    • Egypt
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
    • Israel
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
    • Saudi Arabia
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
    • UAE
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
    • Rest of Middle East
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
  7. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Takeda Pharmaceutical Company Limited.
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Sanofi S.A.
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Octapharma AG
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Swedish Orphan Biovitrum AB
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Baxter International Inc.
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Biogen Inc.
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Bayer AG
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • CSL Behring
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Ferring B.V.
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Pfizer, Inc.
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Kedrion
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Novo Nordisk A/S
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Grifols S.A
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Sangamo Therapeutics, Inc.
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Spark Therapeutics, Inc.
        • Company Overview
        • Technology Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
    • Analyst Views
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 21 market data tables and 20 figures on "Middle East and Turkey Hemophilia Treatment Market” – Countrywide forecast to 2027”.

Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner